EFFECT OF DAPAGLIFLOZIN, SITAGLIPTIN AND METFORMIN COMBINATION ON SOME METABLIC RISK FACTORS IN IRAQI PATIENTS WITH TYPE-2 DIABETES MELLITUS

Abstract

Diabetes Mellitus is a metabolic disease that requires effective long-term management to achieve optimal glycemic control and minimize chronic complications that may be due to the effect of uncontrolled metabolic risk factors (hypertension, dyslipidemia, and obesity). This study aims to obtain the effect of the combination therapy (Dapagliflozin/Sitagliptin/Metformin) on metabolic risk factors in patients with type 2 diabetes mellitus. A Retrospective cohort study was conducted during the period from February to June 2022. The study involved 50 patients with type 2 diabetes mellitus. Glycated haemoglobin (HbA1c) and lipid profile analysis; in addition to blood pressure and body mass index (BMI) measurements were obtained. The mean systolic blood pressure, HbA1c and BMI before treatment were 131.76±22.49 mmHg, 11.41±2.23% and 31.27±3.92 kg/m2, respectively. They were significantly decreased to 123.44±14.28mmHg, 7.60±1.56%, 30.09±3.54 kg/m2, respectively after treatment. Similarly, the  median level of TG, TC, LDL, HDL and vLDL levels before treatment was 153.5 mg/dl, 190.0 mg/dl, 105.0 mg/dl, 35.0 mg/dl and 30.7 mg/dl, respectively, and became 145.0 mg/dl, 154.0 mg/dl, 88.0 mg/dl, 42.0 mg/dl and 28.0 mg/dl, respectively after treatment with significant differences. In conclusion the improvement in the primary endpoint after three months of medication was significantly observed in HbA1c and BMI, which indicates that this type of combination therapy for patients with type-2 diabetes mellitus is highly favourable and efficient.